propranolol has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 6 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Globally breast cancer accounts for 24." | 5.91 | The Beta2-adrenergic agonist salbutamol synergizes with paclitaxel on cell proliferation and tumor growth in triple negative breast cancer models. ( Bruque, CD; Bruzzone, A; Jabloñski, M; Lüthy, IA; Pérez Piñero, C; Rivero, EM; Rodríguez, MS; Vanzulli, S, 2023) |
| "Using as in vitro models the colorectal cancer cell lines HCT116, HT29, and CT26, and as triple-negative breast cancer models the 4T1, M-406, and MDA-MB-231 cell lines, we evaluated the effect of the drugs combination on the viability, apoptosis, clonogenicity, and cellular migratory capacity." | 1.91 | Potential effect of chloroquine and propranolol combination to treat colorectal and triple-negative breast cancers. ( Anselmino, LE; Baglioni, MV; Menacho-Márquez, M; Reynoso, G; Rico, MJ; Rozados, VR; Scharovsky, OG, 2023) |
| "Globally breast cancer accounts for 24." | 1.91 | The Beta2-adrenergic agonist salbutamol synergizes with paclitaxel on cell proliferation and tumor growth in triple negative breast cancer models. ( Bruque, CD; Bruzzone, A; Jabloñski, M; Lüthy, IA; Pérez Piñero, C; Rivero, EM; Rodríguez, MS; Vanzulli, S, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anselmino, LE | 2 |
| Baglioni, MV | 2 |
| Reynoso, G | 1 |
| Rozados, VR | 1 |
| Scharovsky, OG | 2 |
| Rico, MJ | 2 |
| Menacho-Márquez, M | 1 |
| Jabloñski, M | 1 |
| Rodríguez, MS | 1 |
| Rivero, EM | 1 |
| Bruque, CD | 1 |
| Vanzulli, S | 1 |
| Bruzzone, A | 1 |
| Pérez Piñero, C | 1 |
| Lüthy, IA | 1 |
| Malizia, F | 1 |
| Laluce, NC | 1 |
| Etichetti, CB | 1 |
| Marignac, VLM | 1 |
| Rozados, V | 1 |
| Girardini, J | 1 |
| Menacho Márquez, M | 1 |
| Xie, WY | 1 |
| He, RH | 1 |
| Zhang, J | 1 |
| He, YJ | 1 |
| Wan, Z | 1 |
| Zhou, CF | 1 |
| Tang, YJ | 1 |
| Li, Z | 1 |
| Mcleod, HL | 1 |
| Liu, J | 1 |
| Lee, A | 1 |
| Fraser, SP | 1 |
| Djamgoz, MBA | 1 |
| Choy, C | 1 |
| Raytis, JL | 1 |
| Smith, DD | 1 |
| Duenas, M | 1 |
| Neman, J | 1 |
| Jandial, R | 1 |
| Lew, MW | 1 |
6 other studies available for propranolol and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Potential effect of chloroquine and propranolol combination to treat colorectal and triple-negative breast cancers.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chloroquine; Colorectal Neoplasms; Humans; | 2023 |
The Beta2-adrenergic agonist salbutamol synergizes with paclitaxel on cell proliferation and tumor growth in triple negative breast cancer models.
Topics: Adrenergic Agonists; Albuterol; Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Prolife | 2023 |
Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment.
Topics: Animals; beta Catenin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Chemother | 2021 |
β‑blockers inhibit the viability of breast cancer cells by regulating the ERK/COX‑2 signaling pathway and the drug response is affected by ADRB2 single‑nucleotide polymorphisms.
Topics: Adrenergic beta-Antagonists; Apoptosis; Cell Line, Tumor; Cell Survival; Cyclooxygenase 2; Down-Regu | 2019 |
Propranolol inhibits neonatal Nav1.5 activity and invasiveness of MDA-MB-231 breast cancer cells: Effects of combination with ranolazine.
Topics: Cell Movement; Cell Proliferation; Collagen; Drug Combinations; Female; Gene Expression Regulation, | 2019 |
Inhibition of β2-adrenergic receptor reduces triple-negative breast cancer brain metastases: The potential benefit of perioperative β-blockade.
Topics: Adrenergic beta-2 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Animals; Brain Neoplasms; Ce | 2016 |